FDA Accepts NDA for Ensartinib in Metastatic ALK+ NSCLC

The FDA has accepted a new drug application for ensartinib in metastatic ALK-positive non–small cell lung cancer.

Related Keywords

Giovanni Selvaggi ,Xcovery Holdings , ,Non Small Cell Lung Cancer ,Nsclc ,Ensartinib ,Fda ,